178 related articles for article (PubMed ID: 16804832)
1. New approaches to using FEIBA in the treatment of inhibitor patients.
Berntorp E; Gringeri A; Leissinger C; Négrier C; Key N
Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():22-7. PubMed ID: 16804832
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents.
Ananyeva NM; Lee TK; Jain N; Shima M; Saenko EL
Semin Thromb Hemost; 2009 Nov; 35(8):735-51. PubMed ID: 20169510
[TBL] [Abstract][Full Text] [Related]
3. Current opinion on inhibitor treatment options.
Mathew P
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis in haemophilia with inhibitors: update from international experience.
Carcao M; Lambert T
Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
[TBL] [Abstract][Full Text] [Related]
5. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre.
Smejkal P; Brabec P; Matyskova M; Bulikova A; Slechtova M; Kissova J; Chlupova G; Muzik J; Penka M
Haemophilia; 2009 May; 15(3):743-51. PubMed ID: 19432925
[TBL] [Abstract][Full Text] [Related]
6. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors.
Gomperts ED; Astermark J; Gringeri A; Teitel J
Blood Rev; 2008 Feb; 22 Suppl 1():S1-11. PubMed ID: 18485996
[TBL] [Abstract][Full Text] [Related]
7. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
[TBL] [Abstract][Full Text] [Related]
8. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
Holme PA; Brosstad F; Tjønnfjord GE
Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
[TBL] [Abstract][Full Text] [Related]
9. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.
Zanon E; Milan M; Gamba G; Ambaglio C; Saggiorato G; Spiezia L; Montani N; Prandoni P
Thromb Res; 2015 Dec; 136(6):1299-302. PubMed ID: 26505666
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
Astermark J; Donfield SM; DiMichele DM; Gringeri A; Gilbert SA; Waters J; Berntorp E;
Blood; 2007 Jan; 109(2):546-51. PubMed ID: 16990605
[TBL] [Abstract][Full Text] [Related]
11. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.
López-Fernández MF; Altisent Roca C; Álvarez-Román MT; Canaro Hirnyk MI; Mingot-Castellano ME; Jiménez-Yuste V; Cid Haro AR; Pérez-Garrido R; Sedano Balbas C
Thromb Haemost; 2016 May; 115(5):872-95. PubMed ID: 26842562
[TBL] [Abstract][Full Text] [Related]
12. FEIBA: mode of action.
Turecek PL; Váradi K; Gritsch H; Schwarz HP
Haemophilia; 2004 Sep; 10 Suppl 2():3-9. PubMed ID: 15385040
[TBL] [Abstract][Full Text] [Related]
13. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.
Holme PA; Glomstein A; Grønhaug S; Tjønnfjord GE
Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748
[TBL] [Abstract][Full Text] [Related]
14. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
Steen Carlsson K; Astermark J; Donfield S; Berntorp E
Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
[TBL] [Abstract][Full Text] [Related]
15. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies.
Teitel JM; Sholzberg M
Blood Rev; 2013 Mar; 27(2):103-9. PubMed ID: 23452718
[TBL] [Abstract][Full Text] [Related]
16. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor.
Hayashi T; Tanaka I; Shima M; Yoshida K; Fukuda K; Sakurai Y; Matsumoto T; Giddings JC; Yoshioka A
Haemophilia; 2004 Jul; 10(4):397-400. PubMed ID: 15230956
[TBL] [Abstract][Full Text] [Related]
17. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
Franchini M; Coppola A; Tagliaferri A; Lippi G
Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
[TBL] [Abstract][Full Text] [Related]
18. FEIBA safety profile in multiple modes of clinical and home-therapy application.
Luu H; Ewenstein B
Haemophilia; 2004 Sep; 10 Suppl 2():10-6. PubMed ID: 15385041
[TBL] [Abstract][Full Text] [Related]
19. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
Valentino LA
Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
[TBL] [Abstract][Full Text] [Related]
20. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.
Tjønnfjord GE; Holme PA
Vasc Health Risk Manag; 2007; 3(4):527-31. PubMed ID: 17969383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
